RSV vaccine recommended before fall outbreak for high-risk groups

Respiratory Syncytial Virus (RSV) is a significant public health concern, particularly for vulnerable populations. While its initial symptoms mimic the common cold, such as a runny nose, nasal congestion, sore throat, cough, and phlegm, RSV can escalate into life-threatening conditions like pneumonia, especially in the elderly and individuals with weakened immune systems. The virus is classified as a legally designated infectious disease alongside influenza.

Health authorities are emphasizing the importance of vaccination, recommending that high-risk individuals receive the RSV vaccine starting in August. This timing is crucial, as it precedes the main respiratory illness season in the fall and winter, allowing sufficient time for the body to develop immunity. Unlike influenza, RSV outbreaks can begin one to two months earlier, making early vaccination a key preventive strategy.

The Centers for Disease Control and Prevention (CDC) and the Korean Society of Infectious Diseases recommend a single dose of the RSV vaccine for adults aged 50-74 identified as high-risk for severe RSV infection, and for all adults aged 75 and older. This recommendation is based on the understanding that RSV can lead to severe outcomes, including hospitalization, worsening of existing conditions, and even death.

Elderly individuals are particularly susceptible due to age-related declines in immune function and respiratory system resilience. Studies show that over half of hospitalized RSV patients aged 65 and older develop pneumonia. Viral pneumonia caused by RSV is also associated with significantly higher rates of intensive care unit admission, mechanical ventilation, and in-hospital mortality compared to bacterial pneumonia. Beyond initial recovery, RSV infection can have long-term health impacts, with a notable percentage of elderly patients requiring re-hospitalization or experiencing functional decline post-discharge.

Beyond the elderly, other high-risk groups include individuals with chronic conditions such as asthma, COPD, heart failure, and diabetes, as well as the immunocompromised, such as those who have undergone stem cell or organ transplants. International research indicates that these individuals face substantially elevated risks of hospitalization and disease exacerbation when infected with RSV. Dr. Kim Jeong-ho, an infectious disease specialist, stresses that vaccination is the most reliable preventive measure and reiterates the recommendation for early vaccination in late summer.

“

The most certain preventive measure against RSV infection is vaccination. RSV infection begins its epidemic one to two months earlier than the flu, and since it takes about two weeks or more to develop immunity after vaccination, RSV vaccination is recommended from late summer, before the full epidemic begins.